TrialsgrambetaRCTs are beautiful

REWIND

2019

Researching Cardiovascular Events with a Weekly Incretin in Diabetes

In 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.

Result

Efficacy: 3-point MACEHR 0.88 · P = 0.026

Below 1 favours dulaglutide 1.5 mg weekly, above 1 favours placebo.

Also reported: Benefit consistent in patients with and without established CVD.

Original publication
Subtopic
Primary CV prevention
Design
Double-blind RCT, median 5.4 yr
Relevance
Important: one of several pillars.
Source
Gerstein HC, et al. Lancet. 2019;394(10193):121-130.doi 10.1016/S0140-6736(19)31149-3

Discussion & critique

Extended GLP-1 RA benefit into the primary-prevention population: broadened the indication beyond established CVD.

Discussed in podcasts